Revisiting UGT1A1 Pharmacogenetic Testing Before Irinotecan—Why Not? | JCO Oncology Practice
Irinotecan was first approved by the US Food and Drug Administration in 1996, and a quarter century later, it remains a critical drug for the treatment of colorectal, pancreatic, and gastroesophageal cancers. Use of irinotecan in curative-intent therapies has increased in recent years, particularly as part of the fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) regimen in the adjuvant treatment of pancreatic cancer. 1 It seems clear to us that irinotecan will remain an essential cancer
